{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T05:14:27Z","timestamp":1648876467816},"reference-count":8,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2022,3,30]]},"DOI":"10.1536\/ihj.21-664","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T22:24:28Z","timestamp":1648592668000},"page":"408-410","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Strategy for Heart Failure with Reduced Ejection Fraction and Cardiac Amyloidosis"],"prefix":"10.1536","volume":"63","author":[{"given":"Teruhiko","family":"Imamura","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Izumida","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail 2019; 6: 1128-39.","DOI":"10.1002\/ehf2.12518"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tsutsui H, Isobe M, Ito H, <i>et al<\/i>; Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017\/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure- Digest Version. Circ J 2019; 83: 2084-184.","DOI":"10.1253\/circj.CJ-19-0342"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. de Lartigue J. Tafamidis for transthyretin amyloidosis. Drugs Today (Barc) 2012; 48: 331-7.","DOI":"10.1358\/dot.2012.48.5.1808486"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Maurer MS, Schwartz JH, Gundapaneni B, <i>et al<\/i>; ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018; 379: 1007-16.","DOI":"10.1056\/NEJMoa1805689"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kazi DS, Bellows BK, Baron SJ, <i>et al<\/i>. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation 2020; 141: 1214-24.","DOI":"10.1161\/CIRCULATIONAHA.119.045093"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Aimo A, Vergaro G, Castiglione V, Rapezzi C, Emdin M. Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis. Eur J Intern Med 2020; 80: 66-72.","DOI":"10.1016\/j.ejim.2020.05.015"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Swedberg K, Komajda M, Bohm M, <i>et al<\/i>. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85.","DOI":"10.1016\/S0140-6736(10)61198-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Izumida T, Imamura T, Fukui T, <i>et al<\/i>. How to Estimate the Optimal Heart Rate in Patients with Heart Failure with Preserved Ejection Fraction. Int Heart J 2021; 62: 816-20.","DOI":"10.1536\/ihj.20-788"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/2\/63_21-664\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T04:48:38Z","timestamp":1648874918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/2\/63_21-664\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.21-664","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"article-number":"21-664"}}